heptyl-isopropyl-amine | 90105-56-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: heptyl-isopropyl-amine
• 英文别名: Heptyl-isopropyl-amin；N-heptyl-N-isopropylamine；N-(Propan-2-yl)heptan-1-amine；N-propan-2-ylheptan-1-amine
• CAS: 90105-56-9
• 化学式: C₁₀H₂₃N
• mdl: MFCD11182150
• 分子量: 157.299
• InChiKey: ZTHAILDTJQRPPR-UHFFFAOYSA-N

物化性质

• 沸点：
  194.6±8.0 °C(Predicted)
• 密度：
  0.775±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  heptyl-isopropyl-amine 在 氯化亚砜 、 苯 作用下， 生成 heptyl-isopropyl-(2-pyrrolidino-ethyl)-amine
  参考文献：
  名称：

  Potential Antiviral Agents. II. Analogs of Tetraalkyldiamines

  摘要：

  DOI：

  10.1021/ja01587a030
• 作为产物：
  描述：

  2-氯丙烷 、 庚胺 生成 heptyl-isopropyl-amine
  参考文献：
  名称：

  Derivatives of Dimethylaminoethanol and Dimethylaminoethylamine

  摘要：

  DOI：

  10.1021/ja01125a050

文献信息

• Photometric Characterization of the Reductive Amination Scope of the Imine Reductases from<i>Streptomyces tsukubaensis</i>and<i>Streptomyces ipomoeae</i>
  作者：Philipp Matzel、Lukas Krautschick、Matthias Höhne

  DOI：10.1002/cbic.201700257

  日期：2017.10.18

  reductive amination catalyzed by two promising imine reductases is established in a rapid photometric NADPH assay. Substrates ranging from aldehydes to ketones and from primary to secondary amines are accepted, thus giving access to various secondary and tertiary amine products.

  两种酶663种组合：在快速光度NADPH分析中确定了由两种有前途的亚胺还原酶催化的还原胺化中的底物范围。可以接受从醛到酮以及从伯胺到仲胺的各种底物，因此可以使用各种仲胺和叔胺产品。
• TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
  申请人：Arvinas, Inc.

  公开号：US20180155322A1

  公开（公告）日：2018-06-07

  The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，这些化合物可用作雌激素受体（目标蛋白）的调节剂。特别是，本公开涉及包含在一段至少有一种Von Hippel-Lindau配体、一种cereblon配体、凋亡抑制蛋白配体、小鼠双分钟同源2配体或其组合的双功能化合物，这些配体与相应的E3泛素连接酶结合，在另一端有一个与目标蛋白结合的部分，使得目标蛋白被置于泛素连接酶附近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白降解/抑制相关的广泛药理活性。可以通过本公开的化合物和组合物治疗或预防由目标蛋白聚集或积累引起的疾病或障碍。
• [EN] ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT (ADC) AVEC DES INHIBITEURS DE NAMPT
  申请人：BAYER PHARMA AG

  公开号：WO2021013693A1

  公开（公告）日：2021-01-28

  Conjugate of a binder having formula (AA) wherein AB stands for a binder, Z' stands for a linker, D stands for an active component which is a NAMPT inhibitor and its use as pharmaceuticals.

  一个具有化学式（AA）的粘合剂的共轭物，其中AB代表粘合剂，Z'代表连接剂，D代表一种活性成分，即NAMPT抑制剂，并且其用作药物。
• [EN] TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM<br/>[FR] ESPÈCE D'ALPHA-SYNUCLÉINE ABERRANTE CIBLÉE ET UBIQUITINATION INDUITE ET CLAIRANCE PROTÉOSOMIQUE PAR CO-RECRUTEMENT D'UN SYSTÈME E3-LIGASE
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2021257650A1

  公开（公告）日：2021-12-23

  Disclosed are bispecific compounds (degraders) that target α-synuclein protein for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat neurodegenerative diseases.

  揭示了一种针对α-突触核蛋白进行降解的双特异性化合物（降解剂）。还揭示了含有这些降解剂的药物组合物以及利用这些化合物治疗神经退行性疾病的方法。
• [EN] MULTICYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS MULTICYCLIQUES ET LEURS UTILISATIONS
  申请人：KARYOPHARM THERAPEUTICS INC

  公开号：WO2017117447A1

  公开（公告）日：2017-07-06

  The present invention relates to multicyclic compounds containing a urea or a guanidine moiety, or pharmaceutically acceptable salts or compositions thereof represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof and pharmaceutical comopositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disesase) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

  本发明涉及含有脲基或胍基部分的多环化合物，或其结构式（IA）所代表的药学上可接受的盐或组合物，或其药学上可接受的盐，以及包含这些多环化合物的药物组合物。该发明还涉及一种治疗癌症（如淋巴瘤，如袖珍细胞淋巴瘤）、神经退行性疾病、炎症性疾病或免疫系统疾病（如T细胞介导的自身免疫疾病）的方法，该方法包括向需要的受试者施用本发明化合物的治疗有效量，或其药学上可接受的盐，或包含本发明化合物的组合物，或其药学上可接受的盐。